Bladder Urothelial Carcinoma In Situ
NCI Definition: A flat urothelial lesion of variable thickness in the bladder, devoid of papillary structures containing cytologically malignant cells. (WHO 2016) 
There are 4 clinical trials for bladder urothelial carcinoma in situ, of which 4 are open and 0 are completed or closed. Of the trials that contain bladder urothelial carcinoma in situ as an inclusion criterion, 1 is phase 1 (1 open), 2 are phase 2 (2 open), and 1 is phase 3 (1 open).
Oncolytic adenovirus encoding gm-csf, cetrelimab, and gemcitabine-releasing intravesical system are the most common interventions in bladder urothelial carcinoma in situ clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.